General
Preferred name
DEXTROAMPHETAMINE
Synonyms
DEXTROAMPHETAMINE SULFATE ()
dexamfetamine ()
DEXTROAMPHETAMINE MONOSACCHARATE ()
DEXTROAMPHETAMINE SACCHARATE ()
DEXTROAMPHETAMINE ADIPATE ()
DEXTROAMPHETAMINE PHOSPHATE ()
D-Amphetamine (hydrochloride) ()
Dextroamphetamine resin complex ()
Dexamphetamine ()
Amphetamine, d- ()
d-Amphetamine ()
Dexanfetamina ()
NSC-73713 ()
Amfetamine, (s)- ()
Dexidrine ()
Xelstrym ()
Dextrostat ()
Dexedrine spansule ()
Dexampex ()
Dextroamphetamine sulfate cii ()
Dexamphetamine sulfate ()
Dexedrine ()
Dexamphetamine sulphate ()
Dextroamphetamine sulfate component of mydayis ()
D-amphetamine hemisulfate salt ()
Dexamfetamine sulfate ()
Dextroamphetamine sulfate component of delcobese ()
Ferndex ()
NSC-27104 ()
Dextroamphetamine sulphate ()
D-amphetamine adipate ()
Dextroamphetamine adipate component of delcobese ()
Dextroamphetamine saccharate component of mydayis ()
Dexamfetamine hemisaccharate ()
Dexamfetaphine saccharate ()
Dexamfetamine saccharate ()
D-amphetamine saccharate ()
Bar-dex ()
Depalone ()
Dexamfetamine phosphate ()
Amfe-dyn ()
D-Amphetamine (hemisulfate) ()
P&D ID
PD009473
CAS
1462-73-3
60-15-1
51-62-7
300666-47-1
51-63-8
51-64-9
Tags
available
drug
drug candidate
Approved by
FDA
First approval
1996
1960
1955
1975
Drug indication
Narcolepsy
Attention deficit hyperactivity disorder
Drug Status
approved
illicit
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Dextroamphetamine is a noncatecholamine, sympathomimetic amine that acts as a CNS stimulant[Label]. Dextroamphetamine raises systolic and diastolic blood pressure, acts as a weak bronchodilator, and also acts as a respiratory stimulant[Label]. The general mechanism of action of dextroamphetamine has not been well established[Label].
MOA The exact mechanism of amphetamines as a class is not known. Dextroamphetamine acts by preventing reuptake, increasing release, and stimulating reverse-transport of dopamine in synaptic clefts in the striatum[A177253]. Newer evidence shows amphetamines may also alter the number of dopamine transporters in synaptic clefts[A177220].
INDICATION Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD)[Label].
ROE A third of the drug is eliminated renally[A2505].
TOXICITY Dexrtoamphetamine has been shown to be teratogenic and embryotoxic in mice at 41 times the maximum human dose[Label]. These effects were not seen in rat or rabbit studies, and the effects on human pregnancy have not been studied[Label]. The risk and benefit of use during pregnancy should be weighed as bone deformities, tracheoesophageal fistula, anal atresia, low birthweight, and withdrawl have been reported in the children of mothers who were taking dextroamphetamine during pregnancy[Label]. Mothers should not take amphetamines while nursing as the drug is excreted in breast milk[Label]. Long term effects of dextroamphetamine have not bee determined in pediatric patients and dextroamphetamine should be avoided in children under 3 years[Label].
METABOLISM Dextroamphetamine is metabolized by cytochrome P-450 2D6 in the liver to 4-hydroxyamphetamine and later conjugated by sulfotransferase or glucoronyltransferase[A174292].
ABSORPTION Bioavailability data of dextroamphetamine is not readily available, however there is no difference in bioavailability when taken with or without a meal[Label].
HALF-LIFE 11.75 hours[Label]. In a study of post-stroke patients the half life was 16.0 hours in females and 12.4 hours in males[A2505]. Studies in healthy populations show a half life of 7.9 hours[A177247].
DESCRIPTION Dextroamphetamine was first approved by the FDA in 1955 as dextroamphetamine resin complex in combination with amphetamine complex. (GtoPdb)
Cell lines
0
Organisms
1
Compound Sets
18
Cayman Chemical Bioactives
14204
26204
ChEMBL Approved Drugs
CHEMBL612
CHEMBL3544971
CHEMBL1200782
CHEMBL3989844
ChEMBL Drugs
CHEMBL612
CHEMBL3544971
CHEMBL1200782
CHEMBL3989844
CHEMBL2106669
Concise Guide to Pharmacology 2017/18
2147
Concise Guide to Pharmacology 2019/20
2147
Concise Guide to Pharmacology 2021/22
2147
Concise Guide to Pharmacology 2023/24
2147
DrugBank
DB01576
DrugBank Approved Drugs
DB01576
DrugCentral
841
DrugCentral Approved Drugs
841
DrugMAP
DMMIHVP
DrugMAP Approved Drugs
DMMIHVP
Guide to Pharmacology
2147
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL612
NCATS Inxight Approved Drugs
283TUU52FG
NPC Screening Collection
Other bioactive compounds
External IDs
109
Properties
(calculated by RDKit )
Molecular Weight
135.1
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
1
Aromatic Ring Count
1
cLogP
1.58
TPSA
26.02
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.65
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Therapeutic Class
Central Nervous System Stimulants
Source data